Current FDA-approved pharmacologic options for the prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, alendronate plus D, ibandronate, risedronate, risedronate with 500 mg of calcium carbonate and zoledronic acid), calcitonin, estrogens (estrogen and/or hormone therapy), estrogen agonist/antagonist (raloxifene) and parathyroid hormone [PTH(1-34), teriparatide]. Please see Prescribing Information for specific details of their use.